Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas
© 2023. The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology..
Despite the current progress of treatment, pediatric-type diffuse glioma is one of the most lethal primary malignant tumors in the central nervous system (CNS). Since pediatric-type CNS tumors are rare disease entities and highly heterogeneous, the diagnosis is challenging. An accurate diagnosis is essential for the choice of optimal treatment, which leads to precision oncology and improvement of the patient's outcome. Genome-wide DNA methylation profiling recently emerged as one of the most important tools for the diagnosis of CNS tumors, and the utility of this novel assay has been reported in both pediatric and adult patients. In the current World Health Organization classification published in 2021, several new entities are recognized in pediatric-type diffuse gliomas, some of which require methylation profiling. In this review, we investigated the utility of genome-wide DNA methylation profiling in pediatric-type diffuse glioma, as well as issues in the clinical application of this assay. Furthermore, the combination of genome-wide DNA methylation profiling and other comprehensive genomic assays, which may improve diagnostic accuracy and detection of the actionable target, will be discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Brain tumor pathology - 40(2023), 2 vom: 01. Apr., Seite 56-65 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Otani, Yoshihiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Genome-wide DNA methylation profiling |
|---|
| Anmerkungen: |
Date Completed 20.04.2023 Date Revised 20.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10014-023-00457-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355094398 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355094398 | ||
| 003 | DE-627 | ||
| 005 | 20231226063624.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10014-023-00457-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM355094398 | ||
| 035 | |a (NLM)37004583 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Otani, Yoshihiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.04.2023 | ||
| 500 | |a Date Revised 20.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology. | ||
| 520 | |a Despite the current progress of treatment, pediatric-type diffuse glioma is one of the most lethal primary malignant tumors in the central nervous system (CNS). Since pediatric-type CNS tumors are rare disease entities and highly heterogeneous, the diagnosis is challenging. An accurate diagnosis is essential for the choice of optimal treatment, which leads to precision oncology and improvement of the patient's outcome. Genome-wide DNA methylation profiling recently emerged as one of the most important tools for the diagnosis of CNS tumors, and the utility of this novel assay has been reported in both pediatric and adult patients. In the current World Health Organization classification published in 2021, several new entities are recognized in pediatric-type diffuse gliomas, some of which require methylation profiling. In this review, we investigated the utility of genome-wide DNA methylation profiling in pediatric-type diffuse glioma, as well as issues in the clinical application of this assay. Furthermore, the combination of genome-wide DNA methylation profiling and other comprehensive genomic assays, which may improve diagnostic accuracy and detection of the actionable target, will be discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Genome-wide DNA methylation profiling | |
| 650 | 4 | |a Pediatric brain tumor | |
| 650 | 4 | |a Pediatric-type diffuse glioma | |
| 700 | 1 | |a Satomi, Kaishi |e verfasserin |4 aut | |
| 700 | 1 | |a Suruga, Yasuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ishida, Joji |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Kentaro |e verfasserin |4 aut | |
| 700 | 1 | |a Ichimura, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Date, Isao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain tumor pathology |d 1997 |g 40(2023), 2 vom: 01. Apr., Seite 56-65 |w (DE-627)NLM093286635 |x 1861-387X |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:2 |g day:01 |g month:04 |g pages:56-65 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10014-023-00457-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 2 |b 01 |c 04 |h 56-65 | ||